36th week of 2022 patent applcation highlights part 10 |
Patent application number | Title | Published |
20220280597 | Compositions Comprising Antimicrobial Peptides - A method of treating or preventing a microbial infection in a patient is provided, along with a wound irrigation system and a composition in the form of an irrigation liquid for reducing microbial load or preventing microbial infection in a wound. | 2022-09-08 |
20220280598 | COMPLEMENT INHIBITOR DOSING REGIMENS - Methods and compositions for inhibiting complement are described. | 2022-09-08 |
20220280599 | HLA-DR/CII PEPTIDE COMPLEXES FOR TREATING ARTHRITIS - The present invention relates to HLA-DR/CII peptide complexes comprising a chondroitinbinding peptide at the C-terminal end of the polypeptide comprising the H LA-DR alpha chain and/or the H LA-DR beta chain, wherein the CII peptide is fused to the N-terminus of the H LA-DR alpha chain or the H LA-DR beta chain by a linker peptide, for use in treating chronic inflammatory disease, such as arthritis, in human patients. The lysines in the CII peptide, particularly the first lysine in the CII peptide, may be post-translationally modified. The invention further relates to methods of producing said HLA-DR/CII peptide complexes in mammalian cells. | 2022-09-08 |
20220280600 | GASTRO-RESISTANT MICROENCAPSULATES, AND USES THEREOF TO STIMULATE IN-VIVO ILEAL GLP-1 RELEASE IN A MAMMAL - A cold-gelated mono-nuclear microencapsulate comprises a unitary liquid core encapsulated within a gastro-resistant, ileal-sensitive, polymerized denatured protein membrane shell, wherein the liquid core comprises a GLP-1 release stimulating agent in a substantially solubilised form. The GLP-1 release stimulating agent is a native protein selected from native dairy protein, native vegetable protein or native egg protein. | 2022-09-08 |
20220280601 | METHOD FOR TREATMENT OF HEPATIC CANCER USING REIC/Dkk-3 GENE IN COMBINATION WITH ANTI-TUMOR AGENT - This invention provides a method for treatment of hepatic cancer with the use of an anti-tumor agent in combination with the REIC/Dkk-3 gene. This invention also provides a therapeutic agent for treatment of hepatic cancer used in combination with an anti-tumor agent, which comprises, as an active ingredient, the REIC/Dkk-3 gene. | 2022-09-08 |
20220280602 | ANTICANCER AGENT AND METHOD FOR PREPARATION OF POROUS SILICA PARTICLE - An anticancer drug according to an embodiment of the present disclosure includes porous silica particles having an anticancer active peptide incorporated therein. Nitrogen-containing groups are located on an outer surface of each porous silica particle, and folic acid is bound to at least some of the nitrogen-containing groups, whereby the anticancer drug has an excellent target delivery ability, is of high stability without forming a precipitate in an in-vivo environment, and is applicable to various carcinomas. | 2022-09-08 |
20220280603 | TARGETING OF THE CYTOSKELETON AS A THERAPEUTIC APPROACH FOR NEURODEGENERATIVE DISEASE - In some aspects, the disclosure relates to compositions and methods useful for the modulating the function of the nuclear pore and/or nucleocytoplasmic transport (NCT). In some embodiments, the disclosure relates to methods of treatment of a neurodegenerative disease (e.g., amyotrophic lateral sclerosis). | 2022-09-08 |
20220280604 | Composition for boosting the immune system - There is provided herein a composition for improving one or more health conditions comprising at least one keratin compound and beta-lactoglobulin (LGB) in a ratio of 1:1 to 1:5. | 2022-09-08 |
20220280605 | A Composition And Method For Improving The Profile Of Blood - Use of a peptide or fragment thereof comprising SEQ ID NO. 1, or a peptide or fragment having at least 80% sequence identity thereto, in the manufacture of a medicament for one or more of reducing triglycerides, reducing LDL, reducing sdLDL, reducing glucose, reducing insulin, reducing HbA1c and increasing insulin sensitivity. | 2022-09-08 |
20220280606 | METHOD OF PREPARING A DE-FIBRINATED PLATELET LYSATE, AND USES OF SAID METHOD - This invention relates to the methods of preparation of a growth factor concentrate derived from platelet lysate and modified to be devoid of fibrinogen. Moreover, the present invention concerns therapeutic applications of said growth factor concentrate to enhance mitogenic, osteogenic, chondrogenic and angiogenic abilities. The disclosed preparation can be used immediately, or stored frozen until use, or lyophilized, or mixed with pharmaceutical formulation, such as biodegradable polymer or other delivery vehicles, to make products. | 2022-09-08 |
20220280607 | Treatment of Heart Defects and Conditions in Pediatric Patients - Provided herein are methods of treating congenital heart disease in a patient, such as tetralogy of Fallot, with beta blockers to increase cardiomyocyte endowment in the patient and/or to reduce risk of developing complications originating later from heart diseases, such as myocardial infarction, in the patient. Also provided herein are uses for beta blockers for treating congenital heart disease, such as tetralogy of Fallot, in a patient to increase cardiomyocyte endowment in the patient and/or to reduce risk of developing complications originating later from heart diseases, such as myocardial infarction, in the patient. | 2022-09-08 |
20220280608 | TREATMENT OF DIABETIC RETINOPATHY WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FAB - Compositions and methods are described for the delivery of a fully human post-translaionally modified (HuPTM) monoclonal antibody (“mAh”) or the antigen-binding fragment of a mAh against human vascular endothelial growth factor (“hVEGF”)—such as, e.g., a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment—to the retina/vitreal humour in the eye(s) of human subjects diagnosed with diabetic retinopathy. | 2022-09-08 |
20220280609 | COMBINATION CANCER THERAPY AGENTS AND METHODS - The present disclosure relates, in general, to methods for treating cancer comprising administering to a subject in need thereof an effective amount of CXCL9, CXCL10 or the combination, in combination with an immune checkpoint inhibitor. The CXCL9, CXCL10 or combination may be administered as a polypeptide, a polynucleotide or cells comprising a polynucleotide encoding CXCL9, CXCL10 or both. In one aspect, the treatment is amenable to patients with low or high mutational burden tumors. | 2022-09-08 |
20220280610 | METHOD FOR REDUCING FLU-LIKE SYMPTOMS ASSOCIATED WITH INTRAMUSCULAR ADMINISTRATION OF INTERFERON USING A FAST TITRATION ESCALATING DOSING REGIMEN - A combination and method for treating multiple sclerosis (MS), and for reducing flu-like symptoms associated with administration of an interferon to a patient with MS. The method involves intramuscularly administering the interferon to the MS patient according to an escalating dosing regimen in weeks 1 to 3, and a full therapeutically effective dose of interferon in week 4. In one embodiment of the invention, the escalating dosing regimen comprises administering one quarter of the therapeutically effective dose in week 1, half of the therapeutically effective dose in week 2, and three-quarters of the therapeutically effective dose in week 3. Also provided are titration packages for enabling compliance with a regimen of changing dosage of an interferon over a period of time. | 2022-09-08 |
20220280611 | SOLID COMPOSITION COMPRISING A PYY COMPOUND AND A SALT OF N-(8-(2- HYDROXYBENZOYL)AMINO)CAPRYLIC ACID - The present invention relates to a solid composition comprising a PYY compound and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and their use in medicine. | 2022-09-08 |
20220280612 | GLP-1 RECEPTOR AGONISTS IN DEMENTIA - The present invention relates to improved medical therapies for all forms and stages of dementia involving administration of (i) GLP-1 receptor agonists to subjects with metabolic syndrome or (ii) semaglutide. | 2022-09-08 |
20220280613 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMERS DISEASE - The present application relates to compositions comprising (i) THC; (ii) melatonin; and (iii) insulin and methods of using same to Alzheimer's disease in a subject in need thereof without the psychological impairment and side effects associated with THC. | 2022-09-08 |
20220280614 | Premixed Ultra-Stable Single-Chain Insulin Analogue Formulations - A premixed acidic solution contains two single-chain insulin analogues. One has isoelectric point between 6.5 and 8.0 (SCI-A) and the other has isoelectric point between 4.5 and 6.0 (SCI-B), such that biphasic basal and prandial insulin activity is provided on subcutaneous injection. Each protein is an analogue of a mammalian insulin, such as human insulin, with insertion of engineered C domain of length 5-11 residues; the respective C domains of SCI-A and SCI-B may be different. SCI-A contains a Glycine, Alanine, Serine or Glutamine substitution at position A21 and may contain a basic residue at position A8 and Glutamine at position B13. SCI-B may contain a non-beta-branched substitution at position A8, either Alanine or Glutamic Acid at position A14, and substitutions at positions B28 and/or B29 to confer rapid action. A method of treating a patient comprises administering the insulin analogue or a physiologically acceptable salt thereof to a patient. | 2022-09-08 |
20220280615 | IMMUNE TOLERANT ELASTIN-LIKE RECOMBINANT PEPTIDES AND METHODS OF USE - Disclosed herein, are recombinant polypeptides comprising one or more homologous amino acid repeats fused with an IgG binding domain The recombinant polypeptides can be bound to a therapeutic antibody and used a delivery vehicle to increase the retention time and reduce systemic-related side effects of the therapeutic antibodies. Also disclosed herein are pharmaceutical compositions including the recombinant polypeptides bound to a therapeutic antibody; and methods of administering the same to patients | 2022-09-08 |
20220280616 | Thiosuccinyl-crosslinked Hemoglobin Conjugates and Methods of Use and Preparation Thereof - Provided herein are thiosuccinyl-crosslinked hemoglobin conjugates useful as blood replacement agents and therapeutic proteins, pharmaceutical compositions comprising the same and the methods of use and preparation thereof. | 2022-09-08 |
20220280617 | METHOD FOR SAFELY PRODUCING BOTULINUM NEUROTOXIN - The present invention relates to a method for producing botulinum toxin in various fragments to then be reassembled, for safely producing same. In the present invention, devised is a method in which: botulinum toxin is produced in fragments by cleaving light and heavy chains thereof into two or three pieces, respectively, and then combined as a full-length toxin, thereby allowing high complexity in production, due to toxicity, as well as low safety and economic feasibility, to be overcome; production of water-soluble botulinum toxin is enabled by using bacteria, thereby markedly shortening the production time as compared to existing production methods; and conjugation of the produced fragments with other proteins and nanoparticles is also enabled, thereby increasing the pharmaceutical extensibility of the toxin. | 2022-09-08 |
20220280618 | ANTIBODIES TO CANDIDA AND USES THEREOF - The present invention is directed to antibodies binding to and neutralizing | 2022-09-08 |
20220280619 | DNA VACCINE AGAINST AMYLOID-BETA AND TAU - An object of the present invention is to provide a vaccine that can simultaneously reduce Aβ deposition and tau deposition in the brain by means of a single molecule. The present invention provides a recombinant vector comprising DNA encoding amyloid-β, DNA encoding an immunoglobulin Fc sequence, and DNA encoding tau. | 2022-09-08 |
20220280620 | CROSS-REACTIVE EPITOPE FOR MULTIPLE SCLEROSIS - Provided herein are methods and compositions for diagnosis and treatment of multiple sclerosis. Compositions and methods are provided, relating to novel peptides involved in autoimmune disease. In the experiments described herein, an unbiased approach was used to screen pathogenic CD4+ T cells from patients with multiple sclerosis (MS), and to determine the antigenic specificity of the T cell receptors (TCR) expressed by these pathogenic cells. | 2022-09-08 |
20220280621 | T CELL MANUFACTURING COMPOSITIONS AND METHODS - The generation of antigen specific T cells by controlled ex vivo induction or expansion can provide highly specific and beneficial T cell therapies. The present disclosure provides T cell manufacturing methods and therapeutic T cell compositions which can be used for treating subjects with cancer and other conditions, diseases and disorders personal antigen specific T cell therapy. | 2022-09-08 |
20220280622 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2022-09-08 |
20220280623 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2022-09-08 |
20220280624 | VACCINE COMPOSITIONS COMPRISING C-C MOTIF CHEMOKINE 22 (CCL22) OR FRAGMENTS THEREOF - The present disclosure relates to CCL22 as a T cell target in cancer immunosuppression. | 2022-09-08 |
20220280625 | BRUSH POLYMERS FOR THERAPEUTIC APPLICATIONS - In an aspect, the invention provides therapeutic agents comprising brush polymers that address challenges associated with conventional administration of free therapeutic peptides. In an embodiment, for example, the invention provides brush polymers incorporating one or more therapeutic peptides as side chain moieties. Therapeutic agents of the invention comprising brush polymers include high-density brush polymers including cross-linked brush polymers and brush block copolymers. In an embodiment, brush polymers of the invention exhibit proteolysis-resistant characteristics and maintain their biological function during formulation and administration. The invention also includes methods of making and using therapeutic agents comprising brush polymers. | 2022-09-08 |
20220280626 | CIRCUMSPOROZOITE PROTEINS WITH INCREASED EXPRESSION IN MAMMALIAN CELLS - Mutated and/or truncated malarial circumsporozoite proteins (CSP) and associated nucleic acids that are more stable and highly expressed in mammalian cells are described. The mutated and/or truncated CSP and associated nucleic acids can be expressed to produce malaria vaccine antigens. | 2022-09-08 |
20220280627 | COMPOSITION AND METHOD FOR GENERATING IMMUNITY TO BORRELIA BURGDORFERI - Provided is an immunogenic composition including a peptide, wherein consecutive amino acids of the peptide include at least amino acids 186-193 of SEQ ID NO:1 and one or more adjuvants. In an example, the peptide is covalently linked to an amino acid sequence including SEQ ID NO:2. Also provided is a method of vaccinating a subject against | 2022-09-08 |
20220280628 | SELF-ADJUVANTING YERSINIA OUTER MEMBRANE VESICLE AS A VACCINE AGAINST PLAGUE, ANTHRAX AND PSEUDOMONAS INFECTION - A vaccine platform using a | 2022-09-08 |
20220280629 | ANTIMICROBIAL VACCINE COMPOSITIONS - This invention is directed to antimicrobial vaccine compounds and compositions comprising oligosaccharide β-(1→6)-glucosamine groups having from 3 to 12 glucosamine units linked through a linker group to tetanus toxoid wherein the toxoid is primarily in its monomeric form This invention is also directed to vaccine compositions that provide natural immunity against microbes possessing a cell wall structure that comprises oligosaccharide N-acetyl-β-(1→6)-glucosamine (PNAG) structures. | 2022-09-08 |
20220280630 | VACCINE COMPOSITIONS AND METHODS OF SELECTING ANTIGENS - Described herein are vaccine compositions and methods of selecting an antigen or fragment thereof for the preparation of a vaccine composition. The methods and vaccine compositions described herein are based, in part, on the discovery that certain polypeptides not previously identified or considered for potential use as antigens from pathogenic microorganisms (e.g., | 2022-09-08 |
20220280631 | VIRAL PANDEMIC VACCINE - This invention teaches a means of rapidly producing a vaccine following a viral outbreak and using said vaccine to prevent the outbreak from becoming a pandemic. Said vaccine is composed of multiple immunostimulatory agents (agonists) incorporated in liposomes. Each agonist will bind to its specific cellular receptor and induce the cell to produce type 1 interferons which has strong anti-viral activity. The agonists are Poly IC, ssRNA, CpG-ODN and MPL-A incorporated in a liposomal vaccine. Using multiple different agonists in the vaccine will elicit a stronger innate immune response than using a single agonist. This vaccine can be enhanced by combining a viral antigen with the agonists in the liposome. Said enhanced vaccine will provide immediate and prolonged immunity to viral infection by stimulating both the innate immune response and the adaptive immune response against the virus. | 2022-09-08 |
20220280632 | MALARIA IMMUNOGEN AND METHODS FOR USING SAME - An immunogen useful for treating malaria generally includes an immunogenic carrier and an antigenic malaria circumsporozoite protein (CSP) peptide that includes the peptide NPDPNANPNVDPNAN (amino acids 5-19 of SEQ ID NO:1) linked to the immunogenic carrier. The immunogen may be administered to a subject having or at risk of having malaria. | 2022-09-08 |
20220280633 | VIRUS-LIKE PARTICLE VACCINES - Provided, herein, in certain embodiments are virus-like particles such as synthetic enveloped VLPs or synthetic membrane VLPs. In some embodiments, the VLPs comprise a lipid bilayer. In some embodiments, the VLPs comprise a purified antigen anchored to the lipid bilayer. Some embodiments relate to vaccines comprising the VLP, methods of using the vaccine, and methods of making the vaccine or VLP. | 2022-09-08 |
20220280634 | Vaccines for the Treatment and Prevention of Zoonotic Infections - The invention relates to compositions comprising a nucleic acid that encodes a peptide or a peptide that induces an immune response in an animal or a mammal that is protective against infection by one or more pathogens. In addition, the invention relates to vaccines comprising compositions and to method for treating and preventing an infection in animals and mammals such as humans. | 2022-09-08 |
20220280635 | PARTICLES FOR STIMULATING AN IMMUNE RESPONSE AGAINST VIRAL INFECTIONS - According to some embodiments, a method of reducing the spread of infection by a target pathogen in a host comprises binding a carrier to a target areas of the host's cells to reduce a likelihood that the target pathogen binds to the target areas, thereby blocking at least some of the target areas, and providing a gained advantage to the host's immune system to fight a disease caused by the target pathogen, wherein providing the gained advantage comprises decorating the carrier with epitopes to be used as a vaccination at target cell populations. | 2022-09-08 |
20220280636 | ANTIGENIC GLYCOPROTEIN E POLYPEPTIDES, COMPOSITIONS, AND METHODS OF USE THEREOF - The disclosure relates to HSV glycoprotein E antigenic peptide constructs and HSV protein vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. The present invention directed to immunogenic polypeptides of use for a vaccine against Herpes Simplex Vims (HSV). The polypeptides are glycoprotein E peptides that are mutated to reduce their binding to antibody Fc domain. | 2022-09-08 |
20220280637 | NOVEL IMMUNOTHERAPEUTIC COMPOSITION AND USES THEREOF - The present invention relates generally to an immunotherapeutic composition. More particularly, the present invention relates to an immunotherapeutic composition which interacts immunologically with T lymphocytes in subjects having peanut allergy or allergy to other tree nuts. This composition is preferably immunointeractive with T cells in subjects having an allergy to the Ara h 1 and/or Ara h 2 allergens. The composition of the present invention is useful in the therapeutic or prophylactic treatment of conditions characterised by an aberrant, inappropriate or otherwise unwanted immune response to peanut, Ara h 1 and/or Ara h 2 or derivative or homologue thereof. | 2022-09-08 |
20220280638 | METHODS AND ARTICLES FOR ALLERGIC DESENSITIZATION VIA THE ORAL MUCOSA - Compositions and methods of use for desensitizing a subject to an allergen via regions of the oral mucosa are provided. | 2022-09-08 |
20220280639 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA INTERFERENCE AGENTS TO IMMUNE CELLS - The disclosure features lipid nanoparticles (LNPs) comprising RNA interference agents, such as siRNAs, and methods of delivery thereof to immune cells. The compositions and methods can be used to modulate the activity of the immune cells to which the LNPs are delivered, such as to modulate regulatory or effector immune cell activity. Accordingly, the disclosure provides compositions and methods for modulating immune response, for example, to stimulate immune responses, such as in cancer and infectious diseases, or to inhibit immune responses, such as in autoimmune and inflammatory disorders. | 2022-09-08 |
20220280640 | FORMULATION CONTAINING TLR AGONIST AND METHODS OF USE - Stable aqueous formulations of adjuvant comprising a TLR7/8 agonist or a TLR4 agonist with a helper lipid that are adsorbed to alum are provided. Compositions and methods of using the formulations for stimulating an immune response are also provided. | 2022-09-08 |
20220280641 | METHODS OF TREATMENT USING A LEPTIN RECEPTOR AGONIST ANTIBODY - Provided herein are therapeutic methods of treatment using agonist leptin receptor (LEPR) antibodies, antigen-binding fragments thereof, or compositions comprising the LEPR antibodies or antigen-binding fragments thereof. Such therapeutic methods include treatment for conditions related to metabolic dysfunction, including for example, lipodystrophy, adiposity or obesity, reducing body weight, non-alcoholic fatty liver disease, hyperphagia, hyperglycemia, insulin resistance, dyslipidemia, hepatic steatosis, and infertility. | 2022-09-08 |
20220280642 | METHODS AND COMPOSITIONS FOR ADOPTIVE CELL THERAPY - Provided are methods for multiple administrations of cells for adoptive cell therapy, and for administering cells to subjects having received prior administrations, and compositions and articles of manufacture for use in the methods. The cells generally express recombinant molecules such as recombinant receptors, e.g., chimeric antigen receptors (CARs) and/or other transgenic receptors. The methods can involve administering cells expressing a first or prior receptor(s) and cells expressing a second or subsequent receptor(s), the second or subsequent receptor(s) being distinct from the first, and which generally do not express the first receptor, and/or administering the cells expressing the second receptor to a subject having received the first administration. The methods can provide various advantages, such as improved efficacy in the context an immune response in the subject against the first or prior receptor and/or in the context of antigen loss, downregulation, or modification, following a first or prior administration. | 2022-09-08 |
20220280643 | ANTI-PVRIG ANTIBODIES FORMULATIONS AND USES THEREOF - The present invention is directed to anti-PVRIG antibodies and stable liquid pharmaceutical formulations thereof. | 2022-09-08 |
20220280644 | "TRPswitch" - A STEP FUNCTION CHEMO-OPTOGENETIC LIGAND - Described herein are photoswitchable compounds that can activate TRPA1 channels in neuronal and non-neuronal cells. The TRPswitch molecules allow for optical control of both the activation and deactivation of TRPA1 channels. Such compounds can be used as research tools or therapeutics. | 2022-09-08 |
20220280645 | Pharmaceutical Eutectic Salt Formation - The invention is directed to a pharmaceutical composition that is liquid at 37° C. and 1 atm, comprising a eutectic mixture of at least an active pharmaceutical ingredient (API) salt, a hydrophilic pharmaceutically acceptable eutectic constituent and a polymer solubilizer, and further comprising a precipitation inhibitor (PI). In another aspect, the invention is directed to a method for preparing such a composition. | 2022-09-08 |
20220280646 | COMPOSITIONS AND METHODS INVOLVING POLYMER, SOLVENT AND HIGH VISCOSITY LIQUID CARRIER MATERIAL - Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. For instance, a carrier formulation for controlled release of injectable drugs is disclosed. The formulation may include a non-water soluble high viscosity liquid which may be sucrose acetate isobutyrate, a lactic-acid based polymer which may be a poly(lactic acid)(glycolic acid), and an organic solvent which maintains the composition in a monophasic form at 25° C. in one atmosphere. Drug in the formulation may be released upon administration such that less than 10% (e.g. 2-8%) of drug is released in the first 5 hours; 10% to 80% of the drug is released during a period of 5 hours to 7 days after administration; and 10% to 40% of the drug is released gradually over a period of 7 days to 28 days from initial administration. The drug may be an anti-schizophrenia agent delivered by injection. | 2022-09-08 |
20220280647 | Hydrophobic Peptide Salts for Extended Release Compositions - The present disclosure, relates, in general, to hydrophobic salts of hydrophilic peptides that form low solubility materials in aqueous solutions and are capable of extended or sustained release of the peptide component when administered to a subject. Hydrophobic salts of C-type natriuretic peptides and uses thereof are also disclosed. | 2022-09-08 |
20220280648 | DESIGN AND EFFICIENT SYNTHESIS OF LIPID-FLUORESCEIN CONJUGATES FOR CAR-T CELL THERAPY - The disclosure relates to lipid-fluorescein conjugates, compositions comprising same, and methods of synthesis and use, such as in the treatment of cancer. | 2022-09-08 |
20220280649 | DEGRADERS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) AND USES THEREOF - Disclosed are bispecific compounds (degraders) that target CDK7 for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat disease. | 2022-09-08 |
20220280650 | COMPOUNDS FOR DEGRADING ALPHA-SYNUCLEIN AGGREGATES AND USES THEREOF - The present disclosure provides compounds, compositions and methods useful for the treatment of neurodegenerative diseases, in particular synucleinopathies. | 2022-09-08 |
20220280651 | DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD19 ADC - The present disclosure relates to the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to administration of ADCs which bind to CD19 (CD19-ADCs). | 2022-09-08 |
20220280652 | NON-VIRAL IMMUNO-TARGETING - The disclosure provides compositions and methods for delivering a payload to cells or tissues that express GLUT4. In some embodiments, the compositions comprise an antibody, or fragment or derivative thereof, that specifically binds to glucose transporter 4 (“GLUT4”) protein, and a therapeutic payload conjugated thereto. In some exemplary embodiments, the compositions are useful for methods of treating a disease or condition in a subject with a genetic mutation in a gene encoding dystrophin protein, wherein the payload comprises a nucleic acid encoding a functional dystrophin protein or functional fragment thereof to ameliorate aspects of the disease. | 2022-09-08 |
20220280653 | INTERCELLULAR ADHESION MOLECULE 1 (ICAM1) ANTIBODY DRUG CONJUGATE AND USES THEREOF - The disclosure provides compositions comprising intercellular adhesion molecule 1 (ICAM1) antibody and methods for using the same for therapeutic applications, for example, treating pancreatic cancer and predicting drug response. | 2022-09-08 |
20220280654 | IMPROVED CONJUGATION LINKERS - Provided are β-eliminative linkers suitable for the conjugation of small molecule, peptide, and protein and compounds comprising the linkers. | 2022-09-08 |
20220280655 | New Adeno-Associated Virus (AAV) Variants and Uses Thereof for Gene Therapy - Adeno-associated virus (AAV) is a defective mono-stranded DNA virus, endemic in human population (35-80%). Recurrent clonal AAV2 insertions are associated with the pathogenesis of rare human hepatocellular carcinoma (HCC) developed on normal liver. The aimed of the inventors was to characterize the natural history of AAV infection in the liver. Viral DNA was thus quantified in tumor and non-tumor liver tissues of 1461 patients. Presence of episomal form and viral mRNA expression were analyzed using a DNAse/TaqMan based assay and quantitative RT-PCR. In silico analyses using viral capture data explored viral variants and new clonal insertions. AAV DNA was detected in 21% of the patients equally distributed in 2 major viral subtypes: one similar to AAV2, the other hybrid between AAV2 and AAV13 sequences. Thus the inventors provided an integrated analysis of the wild type AAV infection in the liver with the identification of viral genotypes, molecular forms, helper virus relationship and viral integrations. These findings are important to understand wild type AAV biology and particularly relevant considering the large usage of AAV vector in liver-targeted gene therapy. Thus, the present invention relates to new adeno-associated virus (AAV) variants and uses thereof for gene therapy. | 2022-09-08 |
20220280656 | COMPOSITIONS AND METHODS FOR TREATING SICKLE CELL DISEASE - Peptide nucleic acid (PNA) oligomers that target the β-globin gene and can increase the frequency of recombination of donor oligonucleotide at the site of a Sickle Cell Disease mutation are provided. Nanoparticle formulations for delivering the PNA oligomers and donor oligonucleotides, and potentiating agents for increase the frequency of recombination of the donor oligonucleotide are also provided. Methods of using the PNA oligomers, donor oligonucleotides, nanoparticles, and potentiating agents for treating Sickle Cell Disease are also provided. | 2022-09-08 |
20220280657 | Genetic Construct - The invention relates to the use of genetic constructs, expression cassettes and recombinant vectors comprising such constructs and cassettes for gene therapy and methods for treating neurodegenerative disorders, such as Parkinson's disease (PD). The constructs comprise a promoter operably linked to a first coding sequence, which encodes tyrosine hydroxylase (TH), and a second coding sequence, which encodes GTP cyclohydrolase 1 (GCH1). The second coding sequence is 3′ to the first coding sequence, and the first and second coding sequences are part of a single operon, wherein the genetic construct does not encode aromatic amino acid decarboxylase (AADC). The construct is delivered to the cerebrospinal fluid (CSF) of the subject. | 2022-09-08 |
20220280658 | SATIATION PEPTIDES FOR WEIGHT LOSS AND ALTERED TASTE SENSITIVITY - The present application provides methods and compositions for AAV-mediated delivery of PYY and Glucagon-like Peptide 1 or an analog thereof (e.g., Exendin-4) to a subject (e.g., the saliva of a subject). In some embodiments, compositions and methods for topical delivery of Ex-4 and PYY peptides also are provided. Methods and compositions are useful to promote weight loss and/or altered lipid taste sensitivity, as well as for the treatment of diabetes. | 2022-09-08 |
20220280659 | Targeted Nanoparticles of Well-Defined and Reproducible Sizes - The invention relates to a nanoparticle preparation comprising nanoparticles of well-defined and reproducible sizes, that are substantially free of aggregate formation. | 2022-09-08 |
20220280660 | COMPOSITION FOR ULTRASOUND CONTRAST AGENT, ULTRASOUND CONTRAST AGENT AND PREPARATION METHOD THEREOF - Disclosed are a composition for ultrasound contrast agent, an ultrasound contrast agent, and a preparation method thereof. The composition for ultrasound contrast agent includes a lipid, a stabilizer and an acoustic-induced deformation material; relative to 100 parts by weight of the lipid, the content of the stabilizer is 20 to 100 parts by weight, and the content of the acoustic-induced deformation material is 1 to 15 parts by weight; and the acoustic-induced deformation material is deformed under a specific acoustic wave, and the characteristic response frequency of the acoustic-induced deformation material is 0.01 MHz to 50 MHz. The microbubble ultrasound contrast agent has better stability, thereby it circulates in vivo for a longer time, and has lower mechanical index, so that the inertial cavitation occurs under a low-energy ultrasonic wave. | 2022-09-08 |
20220280661 | GLUCOCORTICOID RECEPTOR RADIOLIGANDS AND METHODS FOR THEIR PREPARATION AND USE - Disclosed herein are compounds useful for detection of glucocorticoid receptor expression and activity via positron emission tomography and related techniques. Methods for preparation and use of the compounds are also described. | 2022-09-08 |
20220280662 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND IMAGING OF CANCER - Compositions and methods for treating, detecting, and diagnosing cancer and other diseases and disorders are disclosed. | 2022-09-08 |
20220280663 | CELLULAR TARGETED PHARMACEUTICALLY ACTIVE SUBSTANCE OR LABEL DELIVERY SYSTEM - The present invention relates to an isolated cellular targeted delivery system comprising a CD45+ leukocyte cell comprising within said cell a complex of one or more iron binding proteins and an active pharmaceutically active substance and/or label as well as methods for producing such isolated cellular targeted delivery system and uses of such system for prophylaxis, therapy, diagnosis or theragnosis, in particular for prophylactic or therapeutic vaccination, therapy of cancer, particularly metastatic cancer or inflammatory diseases. | 2022-09-08 |
20220280664 | SANITIZING WEIGHTED BRACELET - A sanitizing weighted bracelet with a strap body operably configured to define an enclosure to surround a user's limb, at least one raised section operably configured to house and retain at least one metallic weight, and a sanitizing raised section an upper surface at least partially defining an upper surface of the strap body and defining an access aperture, with a front surface defining an aperture, with a rear surface, and defining at least one channel spatially connected to the access aperture and the aperture defined by the front surface of the sanitizing raised section. The sanitizing raised section also includes a flexible sanitizing container disposed therein and that includes a nozzle projecting outwardly from the aperture of the sanitizing raised section. The flexible sanitizing container is operably configured to be accessible through the access aperture and flexed to cause emission of a sanitizing liquid from a nozzle thereon. | 2022-09-08 |
20220280665 | STERILIZATION DEVICE AND A METHOD THEREOF - A sterilization device is disclosed. The device includes a housing that includes a sterilization conveyor chamber. The sterilization conveyor chamber includes a sterilization conveyor system and a tray placed near the sterilization conveyor system. The tray includes multiple compartments to collect objects. The sterilization conveyor chamber includes an UVC-LED source to sterilize the objects when exposed to UVC light. The sterilization conveyor chamber includes an outlet to receive sterilized objects one at a time. The housing includes a packaging chamber coupled to the sterilization conveyor system via the outlet. The packaging chamber envelopes and seals the sterile objects with a preloaded spool of packaging material. The housing also includes an object retrieval chamber comprising a drawer to store and protect the sterilized objects by moving the sterilized objects. | 2022-09-08 |
20220280666 | ULTRAVIOLET IRRADIATION APPARATUS AND ULTRAVIOLET IRRADIATION METHOD - An ultraviolet irradiation device includes an inner cylinder forming a treatment flow path, an inflow portion allowing the object to flow into the treatment flow path, an outer cylinder accommodating the inner cylinder, a light emitting element irradiating the object passing through the treatment flow path with ultraviolet light, an O-ring dividing a space provided between an outer circumferential surface of the inner cylinder and an inner circumferential surface of the outer cylinder into a first chamber through which the object before ultraviolet irradiation passes and a third chamber through which the object after the ultraviolet irradiation passes, and a second chamber communicating with the first chamber through communication holes. The second chamber communicates with the treatment flow path through a plate. | 2022-09-08 |
20220280667 | APPLIANCE DISINFECTION - An appliance disinfecting device with monitoring and safety interlock system that utilizes user detection and sensors to detect touch and can provide user feedback and decorative features. The device can include a UV transmissive material that provides disinfection of hard to reach surfaces or areas safely. The appliance disinfection device can include an automatic interlock to protect a user from UV exposure. The optics used for the UV disinfection allow the device to become a human interface. The device can be connected to the appliance control system which can be connected to a network and cloud interface. | 2022-09-08 |
20220280668 | BIOSECURITY SYSTEM USING MONITORING AND SANITIZATION FOR AN AGRICULTURAL DWELLING - Sanitizing an agricultural facility by placing a chamber having an open interior within the agricultural facility. An item is placed within an open interior of the chamber and a door is interlocked. Then light having a spectral content within a narrow range of wavelengths is provided from at least one lighting device toward the item for a predetermined amount of time to inactivate a microorganism. Simultaneously, ozone may be discharged into the open interior to sanitize the item. Before the door unlocks the ozone within the interior of the chamber is directed to a filter for forming oxygen. Sanitizing the agricultural facility by detect humans, and in response, providing a first light with one spectral content when the human is detected, and providing a second light with a different spectral content within a narrow range of wavelengths to inhibit bacteria growth when humans are not detected. | 2022-09-08 |
20220280669 | SYSTEM AND METHODS FOR STERILIZING ENCLOSED SPACES USING OZONE - Systems and methods for sterilizing an enclosed space using ozone are disclosed herein. Various embodiments of the devices and methods also provide for accelerated degradation of the ozone upon sterilization. The methods can include identifying enclosed spaces, sterilizing enclosed spaces through ozone generation, generating reports and transmitting the reports. The sterilization unit disclosed herein can sterilize a plurality of enclosed spaces, such as a fleet of medical response vehicles. | 2022-09-08 |
20220280670 | Portable Sanitizer Spritzier System - The Portable Sanitizer Spritzier Station as disclosed includes an undercarriage of frontward and backward motion rollers and sidewards rollers configured to ambulate the station in a first mode and to convey carts there through in a second mode and to collect used sanitizer for recycle and refuse. The disclosure also includes an upper structure of clear side panels and clear tarp ends and inside guide rails between conveyor belts and a sanitizer pipe network directing sanitizer upward from a floor thereof and downward from a ceiling thereof. The disclosure further includes a controller configured to determine one of the first and the second modes and to determine a time limit for the sanitizer to be sprayed through the sanitizer pipes and to control the rollers and conveyor belt. | 2022-09-08 |
20220280671 | FACILITY IMMUNE SYSTEM - A facility immune system (FIS) uses time, occupancy, or sensor data to identify or document areas of a facility that need disinfection and that do not need disinfection. The FIS may employ cells respectively in the areas, and the cells may include status indicators for the areas, beacons that interact with mobile devices, and/or sensor systems to sense human activity or other conditions in the areas. The FIS may further control disinfection units to start and end disinfection processes. The FIS may also communicate with facility staff regarding disinfection processes and may provide an administrative interface that enables an administrator to: monitor infection statuses of areas; control, schedule, or provide instructions for disinfection or cleaning processes; and document disinfection information. | 2022-09-08 |
20220280672 | USE IN AN ELECTRIC PERFUME DIFFUSER OF AN AQUEOUS PERFUME COMPOSITION CONTAINING A SURFACTANT AND A PRESERVATIVE - The present invention relates to the use of a scented aqueous composition, in an electric fragrance diffuser operating with a piezoelectric ceramic, characterised in that said scented aqueous composition comprises 0.1% to 0.3% by weight with respect to the total weight of said composition of a fragrance of an essential oil and/or of raw materials of natural or synthetic fragrance, 0.1 to 1% by weight with respect to the total weight of said composition of a fragrance of a non-ionic surfactant agent, and 0.01 to 0.1% by scented weight with respect to the total weight of said composition of a fragrance of a preserving agent. | 2022-09-08 |
20220280673 | BIODEGRADABLE NON-WOVEN FABRIC SHEET - Disclosed is a malodor control system that includes use of a malodor scavenger to sequester a malodor molecule to reduce and/or eliminate the noxious odor the malodor molecule generates. Some embodiments can include use of a substrate as a non-woven fabric sheet as a delivery system for the malodor scavenger. The substrate can include a polymer complexed with active ingredient to lock the active ingredient in place at a surface of the substrate via a binder so that the active ingredient is present at a predetermined activity level. After interacting with malodor molecules, at least some of the active ingredient migrates via passive diffusion to the substrate surface to maintain the predetermined activity level. Embodiments of the substrate are made from a blend of polyester and rayon, wherein rayon is made using viscose, allowing the substrate to be biodegradable and to handle an increased load of active ingredient. | 2022-09-08 |
20220280674 | FILTER AND FILTERING SYSTEM INCLUDING THE SAME - A filter and a filter system including the filter. The filter includes a porous filter frame having a first upstream-side surface, and a second downstream-side surface based on a thickness direction, the porous filter frame filtering particulate matter. A copper material layer is disposed on at least a portion of the first upstream-side surface of the filter frame. | 2022-09-08 |
20220280675 | BIOAEROSOL INACTIVATOR UVC ANTIMICROBIAL REACTOR - An apparatus for inactivating bioaerosol, comprising an enclosure having lumen walls forming a lumen, said lumen having a lumen input opening and a lumen output opening; a ventilator arranged for forcing an air flow through said lumen; in a cleaning section of said lumen, a source of ultraviolet light arranged to irradiate with ultraviolet light all the air passing through said lumen along a length of said cleaning section; an output muffler arranged for reducing a noise of said air flow in output of said lumen output opening; and a downstream turn section of said lumen, downstream said cleaning section of said lumen, arranged for changing a direction of said air flow such that no ultraviolet light in said cleaning section of said lumen is detectable at said lumen output opening. | 2022-09-08 |
20220280676 | System and Method for Air Purification and Sterilization - A system and method for an air purification assembly that creates high volume, sterilized straight-line airflow with a significant reduction in electricity consumption utilizing counter rotation of two propellers mounted in reverse to create linear airflow and thrust that sucks in air through an inlet and blows the air out through an outlet. Air purification assembly may also sterilize the air as it passes through light utilizing a light core system with a ring-shaped assembly that has one or more UV-C LEDs that may kill bio-organisms within proximity to the air purification assembly while dissipating the heat created by the UVC LED lights in the light core system. | 2022-09-08 |
20220280677 | PHOTOCATALYST FOR AIR PURIFICATION, AND CERAMIC CATALYST FILTER AND AIR PURIFICATION DEVICE INCLUDING THE SAME - A photocatalyst for air purification, a photocatalyst film including the photocatalyst, and an air purification device including the photocatalyst. The photocatalyst for air purification includes: a first metal oxide particle having ultraviolet absorptivity, and fluorine bound to a surface of the first metal oxide particle; second metal oxide particles present on the surface of the first metal oxide particle. The use of the photocatalyst for air purification to remove or degrade volatile organic compounds (VOCs) and viruses. | 2022-09-08 |
20220280678 | VENTILATION SEAT OF VEHICLE - A ventilation seat of a vehicle is proposed. The ventilation seat includes a ventilation pipe mounted in a seat of the vehicle and configured to suck indoor air and to discharge air toward a surface of the seat, a catalytic converter provided in an air flow path of the ventilation pipe, and configured to clean air passing through the air flow path when light is emitted, and a light source assembly provided on an inner wall of the air flow path of the ventilation pipe and arranged to face the catalytic converter to emit the light toward the catalytic converter. | 2022-09-08 |
20220280679 | Prophylactic Gel Compositions and Use as Barriers to Bacterial and Viral Colonization - Gel compositions for use as a barrier for microbial attachment and growth on a surface are provided. The gel compositions can prevent crystal formation, for example, calcium-based stones in biological systems. The gel compositions can enhance function of mucosal barriers against microbial adhesion. Specific compositions for anti-bacterial and anti-viral use are provided. | 2022-09-08 |
20220280680 | COATED SILK FILMS, METHODS FOR THE PRODUCTION THEREOF AND USES THEREOF - The present invention relates to coated silk films. Further, the present invention relates to pharmaceutical or cosmetic compositions comprising the coaled silk films. Furthermore, the present invention relates to coated silk films or pharmaceutical compositions comprising the coated silk films for use in medicine. In addition, the present invention relates to methods of producing the coated silk films. | 2022-09-08 |
20220280681 | WOUND DRESSING MATERIAL AND METHODS OF MAKING AND USING THE SAME - A wound dressing material comprises a base fiber web, a wound-contact scrim, and an antimicrobial layer. The wound-contact scrim comprises water-sensitive fibers comprising a copolymer comprising divalent hydroxyethylene monomer units and divalent dihydroxybutylene monomer units. The antimicrobial layer is sandwiched between the base fiber web and the wound-contact scrim. The wounds dressing material may be contacted with an exposed surface of a wound. A method of making the wound dressing material is also disclosed. | 2022-09-08 |
20220280682 | ANTIMICROBIAL COMPOSITIONS AND ARTICLES COMPRISING THE SAME - The present disclosure provides a solid composition that includes a polycarboxylic acid chelator component mixed with a water-soluble plasticizer component, and a water-soluble or water-dispersible polymer dissolved and/or dispersed in the plasticizer component. The water-soluble plasticizer component has a boiling point >105° C. and has a formula weight of less than 5000 atomic mass units. The composition comprises <10 wt % of a solvent that has a boiling point ≤100 degrees C. When mixed with deionized water at a 1:9 mass ratio, the composition forms an aqueous mixture having a pH of about 2.5-5.5. Articles that include a substrate with a first major surface having a layer comprising the composition adhered to the first major surface are also provided. Methods of treating a biofilm or a wound site with the articles are also provided. | 2022-09-08 |
20220280683 | ELASTOMER COMPOSITION - A composition based on triblock copolymers of the ABA type, including two styrene thermoplastic terminal blocks A, and an elastomer central block B which is a saturated olefin, and at least one polyisobutene having a very low molecular weight and optionally a diblock copolymer of AB. The present composition exhibits advantageous properties which are similar to those of silicone elastomers. Also, a dressing including such an elastomeric composition. | 2022-09-08 |
20220280684 | BIOCOMPATIBLE HYDROGEL COMPRISING HYALURONIC ACID AND POLYETHYLENE GLYCOL - The present invention relates to a biocompatible hydrogel comprising hyaluronic acid and polyethylene glycol, and more particularly, to a biocompatible hydrogel prepared by inducing inter-molecular and/or intra-molecular cross-linking of hyaluronic acid and polyethylene glycol only by irradiating radiation without adding a reactor, a chemical cross-linking agent, or the like, a method for preparing the same, and the use thereof. | 2022-09-08 |
20220280685 | ELASTOMER COMPOSITION - A composition based on triblock copolymers of the ABA type, including two styrene thermoplastic terminal blocks A, glassy at use temperature, and an elastomeric central block B which is a saturated olefin, at least one linear polymer of the polyisobutene type having a very low molecular weight and specific crosslinked polymer particles. The composition exhibits advantageous adhesion and holding properties on the skin which are similar to the properties obtained by matrices based on silicone elastomers. They also exhibit particularly interesting cohesion. | 2022-09-08 |
20220280686 | BONE REGENERATIVE AGENT AND METHOD OF USING SAME - Provided is a bone regenerative agent which can repair a bone defect site with preventing from remaining at the bone defect site. The bone regenerative agent comprises zinc subcarbonate containing hydrozincite. It is preferred that the zinc subcarbonate has a Zn2+ ion elution amount of 0.1 ppm by mass or more after an elution test and also has a pH value of 7.2 or more and less than 8.3 after an elution test. It is preferred that some carbonate ions in the hydrozincite are substituted by sulfate ions or chloride ions. It is preferred that the bone regenerative agent is applied to a bone defect site. | 2022-09-08 |
20220280687 | METHOD FOR CONSTRUCTING BONE MORPHOGENETIC PROTEIN SLOW-RELEASE SYSTEM - To solve the problem that an excellent carrier material is absent in a storage and use process of the bone morphogenetic protein, based on self-polymerization universality of dopamine, the positively-charged polyelectrolyte, the negatively-charged polyelectrolyte and the ceramic powder with biological activity are integrated onto the titanium base material in a layer-by-layer assembly mode to construct a bone morphogenetic protein slow-release system, so that long-acting slow release, on a lesion part, of the bone morphogenetic protein is achieved. The slow-release system has the advantages of being high in surface modulus, stable, resistant to radiation, good in biocompatibility, and the like, can effectively promote osteogenic differentiation of the mesenchymal stem cells, and can be expected to effectively promote bone repair. | 2022-09-08 |
20220280688 | IODINE-INFUSED ULTRA HIGH MOLECULAR WEIGHT POLYETHYLENE - Various embodiments disclosed relate to an implant including a crosslinked iodine-infused polyethylene. In various embodiments, the implant can be made by exposing the polyethylene to a source of iodine such that the polyethylene is infused with iodine. In various embodiments, a method of preventing microbe formation on or around an implant includes implanting a crosslinked iodine-infused implant comprising polyethylene, wherein iodine is released gradually from the implant after the implantation. | 2022-09-08 |
20220280689 | CROSS-LINKED PROTEIN FOAMS AND METHODS OF USING THEREOF A POLYVALENT CELLULAR SCAFFOLD - In one embodiment, the present invention provides a composition, wherein the composition is a porous scaffold, wherein the pores of the scaffold are from 1 to 500 microns, the composition comprising: a) a cross-linkable protein selected from the group consisting of collagen and gelatin; b) a cross-linker which induces cross-linking of the cross-linkable protein; and c) a liquid. | 2022-09-08 |
20220280690 | REINFORCED COLLAGEN DEVICE FOR SOFT TISSUE REPAIR - Disclosed herein are embodiments of orthopedic devices. In several embodiments, orthopedic device comprises a biocompatible covering. In several embodiments the biocompatible covering is a collagen-based material. In several embodiments, the collagen-based material is crosslinked using an epoxide-based crosslinking agent (e.g., a diepoxide, triepoxide, etc.). In several embodiments, after a precursor crosslinked collagen-based material is prepared (e.g., by subjecting it to crosslinking conditions), residual crosslinking agent in the precursor material is quenched. In several embodiments, it has been surprisingly found that, by subjecting the precursor crosslinked collagen based material to a quenching reaction (to provide the crosslinked collagen-based material), improved properties are obtained (e.g., lower toxicity lower cytotoxicity, etc.). In several embodiments, the crosslinked collagen-based material is fabricated into an orthopedic device or used to prepare an orthopedic device (e.g., implant). | 2022-09-08 |
20220280691 | PHOTOCURABLE COMPOSITION - A photocurable composition for 3D printing includes a) at least one photocurable prepolymer chosen from the group consisting of functionalized gelatin bearing a first functional group and functionalized decellularized extracellular matrix bearing a second functional group; b) at least one solvent, the solvent being formamide; and c) at least one photoinitiator. | 2022-09-08 |
20220280692 | SURFACE HARDENING FOR A DENTAL IMPLANT - The present invention relates to a Group IV metal or alloy component having a protective oxide surface layer, the Group IV metal or alloy component having a core hardness, a diffusion zone having oxygen in solid solution in the range of a level providing a hardness of 120% of the hardness of the material core to the saturation level of the Group IV metal or alloy, and a Group IV metal oxide layer at the surface of the component, the diffusion zone being between the Group IV metal oxide layer and the material core. In another aspect, the invention relates to a method of producing a protective oxide surface layer on a Group IV metal or alloy comprising: providing a workpiece of a Group IV metal or alloy, oxidising the Group IV metal or alloy in a first and a second oxidation step. | 2022-09-08 |
20220280693 | TISSUE DERIVED POROUS MATRICES AND METHODS FOR MAKING AND USING SAME - Tissue derived porous matrices for treating wounds are provided, as well as methods for making and using them. The tissue derived porous matrices comprise processed tissue of any of several types, such as dermis, adipose, etc., and have a plurality of interconnected pores which allow fluid flow through the matrices. The tissue derived matrices are biocompatible resorbable matrices which remodel with native tissue and facilitate and enhance cell infiltration and tissue ingrowth into the matrices during the wound healing process, thereby enhancing wound healing and tissue remodeling when implanted into a patient. The tissue derived matrices are useful with reduced or negative pressure wound healing methods and systems, without the need to repeatedly revisit the treatment site and remove previously implanted matrices. | 2022-09-08 |
20220280694 | DETERGENT-FREE DECELLULARIZED EXTRACELLULAR MATRIX PREPARATION METHODS AND BIOINKS FOR 3D PRINTING - A detergent-free decellularized ECM preparation method, a detergent-free decellularized ECM in a powder form and in a liquid form, a method of preparation of a primary bioink, the primary bioink, a method of preparation of a vascular bioink, the vascular bioink, a three dimensional structure including the primary bioink and/or the vascular bioink and a method of preparation of the three-dimensional structure. | 2022-09-08 |
20220280695 | SEALING OF DECELLULARIZED AND RECELLULARIZED ENGINEERED ORGAN GRAFTS - The disclosure provides for methods of sealing of decellularized and recellularized engineered organ grafts, thereby providing a reinforced (fortified) decellularized and recellularized engineered organ graft. | 2022-09-08 |
20220280696 | METHODS, SUBSTRATES, AND SYSTEMS USEFUL FOR CELL SEEDING OF MEDICAL GRAFTS - Described are methods, cell growth substrates, and devices that are useful in preparing cell-containing graft materials for administration to patients. Tubular passages can be defined in cell growth substrates to promote distribution of cells into the substrates. Also described are methods and devices for preparing cell-seeded graft compositions, methods and devices for preconditioning cell growth substrates prior to application of cells, and cell seeded grafts having novel substrates, and uses thereof. | 2022-09-08 |